

# WISE CVD - Continuation (WISE HFpEF)

NCT02582021

---

Status	RECRUITING
Sponsor	Cedars-Sinai Medical Center
Enrollment	220 participants

## Plain Language Summary

---

This study is examining heart disease in women — and some men — focusing on two groups: women experiencing chest pain but without blockages in their major heart arteries, and patients hospitalized for heart failure where the heart's pumping function appears preserved (called HFpEF), to better understand how these conditions develop and how to treat them.

**\*\*You may be eligible if...\*\***

- You are 18 years of age or older
- For the chest pain group: you are a woman experiencing chest pain or an equivalent symptom and are scheduled for a heart artery imaging procedure (coronary angiography)
- For the heart failure group: you have been hospitalized with signs and symptoms of heart failure, your heart's pumping function is preserved (ejection fraction of 45% or higher), and you have evidence of abnormal heart filling pressure

**\*\*You may NOT be eligible if...\*\***

- For the chest pain group: you have a significant blockage in a coronary artery (50% or more), you recently had a heart attack, you need valve surgery, or you are in cardiogenic shock
- For the heart failure group: your heart pumping function is reduced (below 45%), you recently had a heart attack, you have significant valve disease, severe lung disease, severe anemia, BMI above 40, or very high blood pressure at time of entry
- Either group: you have end-stage kidney or liver disease, cannot give consent, have an allergy to gadolinium contrast dye, or cannot have an MRI

Talk to your doctor to see if this trial is right for you.

## Key Eligibility Criteria

---

### Inclusion (11)

- For the new cohort n=120 women undergoing coronary angiography:
  - Symptomatic angina or anginal equivalent
  - Age ≥ 18
  - Participant is willing to give written informed consent
- For the cohort n=100 women and men hospitalized for HFpEF (defined by ESC guidelines):  
... and 6 more (see full listing online)

### Exclusion (28)

- For the new cohort n=120 women undergoing invasive coronary angiography:
  - Obstructive CAD ≥ 50% luminal diameter stenosis in ≥ 1 epicardial coronary artery
  - STEMI within 3-7 days post MI, or Acute coronary syndrome/NSTEMI with symptoms or signs of acute myocardial ischemia within the last 12 to 24 hours prior to the research procedure, as outlined in ACC/AHA guidelines.
  - Primary valvular heart disease clearly indicating the need for valve repair or replacement
- Patients with concurrent cardiogenic shock or requiring inotropic or intra-aortic balloon support or LVEF < 45%

<https://clinicaltrials.gov/study/NCT02582021>  
... and 23 more (see full listing online)

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://ClinicalTrials.gov). Generated by [ClinicalTrialsFinder.org](https://ClinicalTrialsFinder.org).

## Locations (1 total)

---

Cedars-Sinai Women's Heart Center, Los Angeles, California, United States